Martingale Asset Management L P lifted its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 158,554 shares of the company’s stock after acquiring an additional 5,147 shares during the quarter. AbbVie accounts for approximately 0.9% of Martingale Asset Management L P’s investment portfolio, making the stock its 17th biggest holding. Martingale Asset Management L P’s holdings in AbbVie were worth $36,228,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of ABBV. Chelsea Counsel Co. purchased a new position in AbbVie in the 3rd quarter valued at about $26,000. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the 4th quarter valued at about $28,000. Westend Capital Management LLC purchased a new position in AbbVie in the 4th quarter valued at about $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie in the 3rd quarter valued at about $31,000. Finally, Legacy Wealth Managment LLC ID lifted its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
- Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
- Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
- Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on ABBV
AbbVie Trading Up 1.2%
NYSE ABBV opened at $227.54 on Friday. The stock has a market cap of $402.02 billion, a PE ratio of 112.09, a P/E/G ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The stock has a fifty day simple moving average of $211.05 and a 200-day simple moving average of $219.07.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the firm earned $2.46 EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Research analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles
- Five stocks we like better than AbbVie
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
